Nrf3 promotes the proliferation and migration of triple‑negative <br />breast cancer by activating PI3K/AKT/mTOR and<br />epithelial‑mesenchymal transition

Chen,Wan-Meng; Chen,Wan-Meng; Hu,Qing-Yong; Hu,Qing-Yong; Hou,Wei; Hou,Wei; Chen,Meng-Wei; Chen,Meng-Wei; Chen,Ya-Hui; Chen,Ya-Hui; Tang,Jian-Cai; Tang,Jian-Cai

doi:10.3892/ol.2023.14030

Nrf3 promotes the proliferation and migration of triple‑negative
breast cancer by activating PI3K/AKT/mTOR and
epithelial‑mesenchymal transition

Authors:
- Wan-Meng Chen
- Qing-Yong Hu
- Wei Hou
- Meng-Wei Chen
- Ya-Hui Chen
- Jian-Cai Tang
View Affiliations

Affiliations: Department of Biochemistry, Institute of Basic Medicine and Forensics Medicine, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Biochemistry, Institute of Basic Medicine and Forensics Medicine, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: August 28, 2023 https://doi.org/10.3892/ol.2023.14030
Article Number: 443
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor erythroid 2‑related factor 3 (Nrf3) is increasingly implicated in multiple types of cancer; however, its function in triple‑negative breast cancer (TNBC) remains unclear. This study aimed to examine the role of Nrf3 in TNBC. Compared with adjacent normal tissues, TNBC tissues expressed higher levels of Nrf3, and its expression was negatively correlated with survival time. Additionally, Nrf3 knockdown reduced the proliferation and migration of TNBC cells, whereas overexpression of Nrf3 had the opposite effects in vitro and in vivo. Moreover, functional enrichment of TNBC cells overexpressing Nrf3 allowed for the identification of numerous genes and pathways that were altered following Nrf3 overexpression. Further study showed that overexpression of Nrf3 activated the PI3K/AKT/mTOR signaling pathway and regulated the expression of proteins associated with epithelial‑mesenchymal transition. Nrf3 was found to directly bind to p110α promoter regions, as evidenced by luciferase reporter and chromatin immunoprecipitation assays. Furthermore, PI3K inhibitors partially decreased the proliferation and migration of the Nrf3 overexpressing TNBC cells. In conclusion, Nrf3 enhances cellular proliferation and migration by activating PI3K/AKT/mTOR signaling pathways, highlighting a novel therapeutic target for TNBC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
3	Brown M, Tsodikov A, Bauer KR, Parise CA and Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer. 112:737–747. 2008. View Article : Google Scholar : PubMed/NCBI
4	Duffy MJ, McGowan PM and Crown J: Targeted therapy for triple-negative breast cancer: Where are we? Int J Cancer. 131:2471–2477. 2012. View Article : Google Scholar : PubMed/NCBI
5	Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al: Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020. View Article : Google Scholar : PubMed/NCBI
6	Kobayashi A, Ito E, Toki T, Kogame K, Takahashi S, Igarashi K, Hayashi N and Yamamoto M: Molecular cloning and functional characterization of a new Cap'n’ collar family transcription factor Nrf3. J Biol Chem. 274:6443–6452. 1999. View Article : Google Scholar : PubMed/NCBI
7	Motohashi H, O'Connor T, Katsuoka F, Engel JD and Yamamoto M: Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene. 294:1–12. 2002. View Article : Google Scholar : PubMed/NCBI
8	Sekine H and Motohashi H: Roles of CNC transcription factors NRF1 and NRF2 in cancer. Cancers (Basel). 13:5412021. View Article : Google Scholar : PubMed/NCBI
9	Yuan J, Zhang S and Zhang Y: Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases. Toxicol Appl Pharmacol. 360:273–283. 2018. View Article : Google Scholar : PubMed/NCBI
10	Rojo de la Vega M, Chapman E and Zhang DD: NRF2 and the hallmarks of cancer. Cancer Cell. 34:21–43. 2018. View Article : Google Scholar : PubMed/NCBI
11	Derjuga A, Gourley TS, Holm TM, Heng HH, Shivdasani RA, Ahmed R, Andrews NC and Blank V: Complexity of CNC transcription factors as revealed by gene targeting of the Nrf3 locus. Mol Cell Biol. 24:3286–3294. 2004. View Article : Google Scholar : PubMed/NCBI
12	He F, Ru X and Wen T: NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 21:47772020. View Article : Google Scholar : PubMed/NCBI
13	Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY and Deshaies RJ: Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 38:17–28. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kobayashi A: Roles of NRF3 in the hallmarks of cancer: Proteasomal inactivation of tumor suppressors. Cancers (Basel). 12:26812020. View Article : Google Scholar : PubMed/NCBI
15	Braun S, Hanselmann C, Gassmann MG, Auf Dem Keller U, Born-Berclaz C, Chan K, Kan YW and Werner S: Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol. 22:5492–5505. 2002. View Article : Google Scholar : PubMed/NCBI
16	Pepe AE, Xiao Q, Zampetaki A, Zhang Z, Kobayashi A, Hu Y and Xu Q: Crucial role of nrf3 in smooth muscle cell differentiation from stem cells. Circ Res. 106:870–979. 2010. View Article : Google Scholar : PubMed/NCBI
17	Bury M, Le Calvé B, Lessard F, Dal Maso T, Saliba J, Michiels C, Ferbeyre G and Blank V: NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor. Cell Rep. 29:1469–1481.e9. 2019. View Article : Google Scholar : PubMed/NCBI
18	Qian J, Huang C, Zhu Z, He Y, Wang Y, Feng N, He S, Li X, Zhou L, Zhang C and Gong Y: NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer. Carcinogenesis. 43:457–468. 2022. View Article : Google Scholar : PubMed/NCBI
19	Waku T, Nakamura N, Koji M, Watanabe H, Katoh H, Tatsumi C, Tamura N, Hatanaka A, Hirose S, Katayama H, et al: NRF3-POMP-20S proteasome assembly axis promotes cancer development via ubiquitin-independent proteolysis of p53 and retinoblastoma protein. Mol Cell Biol. 40:e00597–19. 2020. View Article : Google Scholar : PubMed/NCBI
20	Yin L, Duan JJ, Bian XW and Yu SC: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
21	Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: Iimplications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
22	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
23	Gjelaj E and Hamel PA: Distinct epithelial-to-mesenchymal transitions induced by PIK3CA (H1047R) and PIK3CB. J Cell Sci. 134:jcs2482942021. View Article : Google Scholar : PubMed/NCBI
24	Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and Larue L: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63:2172–2178. 2003.PubMed/NCBI
25	Cai BQ, Chen WW, Zhao JA, Hou W and Tang JC: Nrf3 Promotes 5-FU resistance in colorectal cancer cells via the NF-κB/BCL-2 signaling pathway in vitro and in vivo. J Oncol. 2021:93555552021. View Article : Google Scholar : PubMed/NCBI
26	Bolger AM, Lohse M and Usadel B: Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics. 30:2114–2120. 2014. View Article : Google Scholar : PubMed/NCBI
27	Kim D, Langmead B and Salzberg SL: HISAT: A fast spliced aligner with low memory requirements. Nat Methods. 12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
28	Trapnell C, William BA, Pertea G, AMortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 28:511–515. 2010. View Article : Google Scholar : PubMed/NCBI
29	Anders S, Pyl PT and Huber W: HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics. 31:166–169. 2015. View Article : Google Scholar : PubMed/NCBI
30	Anders S and Huber W: Differential expression of RNA-Seq data at the gene level-the DESeq package. EMBL; 2013
31	Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Chowdhury A, Katoh H, Hatanaka A, Iwanari H, Nakamura N, Hamakubo T, Natsume T, Waku T and Kobayashi A: Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation. Sci Rep. 7:124942017. View Article : Google Scholar : PubMed/NCBI
34	Immonen A, Haapasaari KM, Skarp S, Karihtala P and Teppo HR: NRF3 decreases during melanoma carcinogenesis and is an independent prognostic marker in melanoma. Oxid Med Cell Longev. 2022:22402232022. View Article : Google Scholar : PubMed/NCBI
35	Waku T, Katayama H, Hiraoka M, Hatanaka A, Nakamura N, Tanaka Y, Tamura N, Watanabe A and Kobayashi A: NFE2L1 and NFE2L3 complementarily maintain basal proteasome activity in cancer cells through CPEB3-mediated translational repression. Mol Cell Biol. 40:e00010–20. 2020. View Article : Google Scholar : PubMed/NCBI
36	Chevillard G, Paquet M and Blank V: Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. Blood. 117:2005–2008. 2011. View Article : Google Scholar : PubMed/NCBI
37	Yu MM, Feng YH, Zheng L, Zhang J and Luo GH: Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells. World J Gastroenterol. 25:1210–1223. 2019. View Article : Google Scholar : PubMed/NCBI
38	Sun J, Zheng Z, Chen Q, Pan Y, Lu H, Zhang H, Yu Y and Dai Y: NRF3 suppresses breast cancer cell metastasis and cell proliferation and is a favorable predictor of survival in breast cancer. Onco Targets Ther. 12:3019–3030. 2019. View Article : Google Scholar : PubMed/NCBI
39	Xie G, Ji A, Yuan Q, Jin Z, Yuan Y, Ren C, Guo Z, Yao Q, Yang K, Lin X and Chen L: Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. Br J Cancer. 110:2514–2523. 2014. View Article : Google Scholar : PubMed/NCBI
40	Tang Y and Wang S, Li Y, Yuan C, Zhang J, Xu Z, Hu Y, Shi H and Wang S: Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. J Nanobiotechnology. 20:2162022. View Article : Google Scholar : PubMed/NCBI
41	Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C and Greabu M: PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci. 22:1732020. View Article : Google Scholar : PubMed/NCBI
42	Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018. View Article : Google Scholar : PubMed/NCBI
43	Aiello NM and Kang Y: Context-dependent EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019. View Article : Google Scholar : PubMed/NCBI
44	Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
45	Bobal P, Lastovickova M and Bobalova J: The Role of ATRA, natural ligand of retinoic acid receptors, on EMT-related proteins in breast cancer: Minireview. Int J Mol Sci. 22:133452021. View Article : Google Scholar : PubMed/NCBI
46	Ren YG, Wang YJ, Hao S, Yang YH, Xiong WD and Qiu L: NFE2L3 promotes malignant behavior and EMT of human hepatocellular carcinoma (HepG2) cells via Wnt/β-catenin pathway. J Cancer. 11:6939–6949. 2020. View Article : Google Scholar : PubMed/NCBI